SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB


          QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934


                      FOR THE QUARTER ENDED March 31, 2006


                             COMMISSION FILE NUMBER:


                               RADIAL ENERGY INC.
             ______________________________________________________
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


                                     NEVADA
         ______________________________________________________________
         (State or other jurisdiction of incorporation or organization)


        Nevada                                           72-1580091
_______________________                     ____________________________________
(State of organization)                     (I.R.S. Employer Identification No.)


                    1313 East Maple St., Bellingham WA 98225
               ___________________________________________________
               (Address of principal executive offices) (Zip Code)


                                Tel: 360-685-4200
                _________________________________________________
                Registrants telephone number, including area code


                             BV Pharmaceutical, Inc.
                 ______________________________________________
                 (Former name, former address and former fiscal
                      year, if changed since last report.)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes /X/ No / /


                                       1


<PAGE>


Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes / / No /X/

Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).  Yes /X/    No /  /

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:

         At March 31, 2006, and as of the date hereof, there were outstanding
         35,065,824 shares of the Registrant's Common Stock, $.001 par value.

Transitional Small Business Disclosure Format: Yes / /   No /X/









































                                        2


<PAGE>


                                TABLE OF CONTENTS


PART I       FINANCIAL INFORMATION

ITEM  1      FINANCIAL STATEMENTS                                         4

ITEM  2      MANAGEMENT'S DISCUSSION OF OPERATIONS AND
             FINANCIAL CONDITION                                         11

PART II      OTHER INFORMATION                                           18

ITEM 6       EXHIBITS AND REPORTS ON FORM 8-K                            18

ITEM 7       SIGNATURES                                                  19









                                       3


<PAGE>


ITEM  1      FINANCIAL STATEMENTS






                               RADIAL ENERGY INC.
                       (FORMERLY BV PHARMACEUTICAL, INC.)

                          (A Development Stage Company)

                          INTERIM FINANCIAL STATEMENTS

                             March 31, 2006 and 2005

                             (Stated in US Dollars)



                                   (Unaudited)












                                       4


<PAGE>

<TABLE>
<CAPTION>


                               RADIAL ENERGY INC.
                       (formerly BV Pharmaceutical, Inc.)
                          (A Development Stage Company)
                             INTERIM BALANCE SHEETS
                      March 31, 2006 and December 31, 2005
                                   (Unaudited)
                             (Stated in US Dollars)




                                                                     March 31         December 31
                                                                       2006              2005
                                                                     _________        ___________
<S>                                                                  <C>               <C>
                                     ASSETS

Current
   Cash                                                              $ 191,244         $   1,211
   Accounts receivable                                                       -             1,000
   Prepaid expenses                                                     10,011                 -
                                                                     _________         _________

                                                                     $ 201,255         $   2,211
                                                                     =========         =========

                                   LIABILITIES

Current
   Accounts payable and accrued liabilities                          $  17,481         $   8,435
   Unearned revenue                                                          -             7,500
                                                                     _________         _________

                                                                        17,481            15,935
                                                                     _________         _________

                        STOCKHOLDERS' EQUITY (DEFICIENCY)

Capital stock - Note 3
   Authorized:
      75,000,000 common stock, $0.001 par value
   Issued:
      35,065,824 common stock (December 31, 2005: 151,065,824)          35,066           151,066
Additional paid-in capital                                              93,180             6,180
Shares subscribed                                                      350,000                 -
Subscription receivable                                               (100,000)                -
Deficit accumulated during the development stage                      (194,472)         (170,970)
                                                                     _________         _________

                                                                       183,774           (13,724)
                                                                     _________         _________

                                                                     $ 201,255         $   2,211
                                                                     =========         =========

</TABLE>


                                       5


<PAGE>

<TABLE>
<CAPTION>


                               RADIAL ENERGY INC.
                       (formerly BV Pharmaceutical, Inc.)
                          (A Development Stage Company)
                        INTERIM STATEMENTS OF OPERATIONS
               for the three-month period ended March 31, 2006 and
               2005 and for the period from June 30, 2000 (Date of
                          Inception) to March 31, 2006
                                   (Unaudited)
                             (Stated in US Dollars)


                                                                                               June 30, 2000
                                                                                                 (Date of
                                                                  Three months ended           Inception) to
                                                                      March 31,                  March 31,
                                                                2006             2005              2006
                                                             ___________     ____________      _____________
<S>                                                          <C>           <C>                   <C>

Revenue
    License fees                                             $         -   $            -        $  24,000
    Other income                                                   8,500              480           10,238
                                                             ___________     ____________        _________

                                                                   8,500              480           34,238
                                                             ___________     ____________        _________

Administrative expenses
    Advertising and promotion                                          -                -            1,001
    Bad debt                                                           -                -            1,000
    Consulting fees - Note 4                                      13,954                -           62,451
    Filing fees                                                    1,981            5,047           14,436
    Intellectual property acquisition costs                            -                -           50,000
    Interest and bank charges                                        473            1,288            8,087
    Investor relations                                            10,000                -           19,996
    Marketing research and development                                 -                -           10,000
    Office and miscellaneous                                       2,713            3,379           15,586
    Professional fees                                              6,868            5,222           47,506
    Rent                                                               -                -              505
    Travel                                                         5,420                -            5,420
    Website maintenance                                                -                -            2,129
                                                             ___________     ____________        _________

                                                                  41,409           14,936          238,117
                                                             ___________     ____________        _________

Loss before other item                                           (32,909)         (14,456)        (203,879)

Other item:
    Gain on note payable forgiven - Note 3                         9,407                -            9,407
                                                             ___________     ____________        _________

Net loss for the period                                      $   (23,502)  $      (14,456)  $     (194,472)
                                                             ===========     ============        =========

Basic loss per share                                         $     (0.00)  $        (0.00)
                                                             ===========     ============

Weighted average number of shares outstanding - Note 3        87,910,268      149,920,400
                                                             ===========     ============

</TABLE>


                                       6


<PAGE>

<TABLE>
<CAPTION>


                               RADIAL ENERGY INC.
                       (formerly BV Pharmaceutical, Inc.)
                          (A Development Stage Company)
                        INTERIM STATEMENTS OF CASH FLOWS
               for the three-month period ended March 31, 2006 and
               2005 and for the period from June 30, 2000 (Date of
                          Inception) to March 31, 2006
                                   (Unaudited)
                             (Stated in US Dollars)

                                                                                                            June 30, 2000
                                                                                                              (Date of
                                                                              Three months ended            Inception) to
                                                                                  March 31,                   March 31,
                                                                            2006              2005              2006
                                                                           ________          ________       _____________
<S>                                                                        <C>               <C>              <C>

Cash Flows used in Operating Activities
   Net loss for the period                                                 $(23,502)         $(14,456)        $(194,472)
   Deduct item not affecting cash:
      Gain on note payable forgiven                                          (9,407)                -            (9,407)
   Changes in non-cash working capital balances related to operations:
      Accounts receivable                                                     1,000                 -                 -
      Prepaid expenses                                                      (10,011)                -           (10,011)
      Accounts payable and accrued liabilities                                9,453               173            17,888
      Unearned revenue                                                       (7,500)                -                 -
                                                                           ________          ________         _________

                                                                            (39,967)          (14,283)         (196,002)
                                                                           ________          ________         _________

Cash flows from Financing Activities
   Capital stock issued                                                           -                 -            99,975
   Decrease in note payable                                                 (20,000)                -           (20,000)
   Convertible debentures                                                         -             1,233            57,271
   Shares subscribed                                                        250,000                 -           250,000
                                                                           ________          ________         _________

                                                                            230,000             1,233           387,246
                                                                           ________          ________         _________

Increase (decrease) in cash during the period                               190,033           (13,050)          191,244

Cash, beginning of the period                                                 1,211            24,964                 -
                                                                           ________          ________         _________

Cash, end of the period                                                    $191,244          $ 11,914         $ 191,244
                                                                           ========          ========         =========

Non-cash Transactions - Note 7

</TABLE>


                                       7


<PAGE>

<TABLE>
<CAPTION>


                               RADIAL ENERGY INC.
                       (formerly BV Pharmaceutical, Inc.)
                          (A Development Stage Company)
                    INTERIM STATEMENT OF STOCKHOLDERS' EQUITY
               (DEFICIENCY) for the period June 30, 2000 (Date of
                          Inception) to March 31, 2006
                                   (Unaudited)
                             (Stated in US Dollars)

                                                                                                       Deficit
                                                                                                     Accumulated
                                                             Additional     Shares     Subs-         During the
                                       Common Stock           Paid-in       Subs-      cription      Development
                                  *Shares      **ParValue     Capital       cribed     receivable       Stage          Total
                                 ___________   __________    __________    ________    __________    ___________     _________
<S>                              <C>           <C>           <C>           <C>         <C>           <C>             <C>

Capital stock subscribed
pursuant to an offering
memorandum for cash
              - at $0.0000002    122,172,000   $ 122,172     $(121,968)    $      -    $        -    $         -     $     204
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, December 31, 2000       122,172,000     122,172      (121,968)           -             -              -           204
Capital stock issued pursuant
to a private placement
               - at $0.0025       27,108,400      27,108        40,663            -             -              -        67,771
               - at $0.05            160,000         160         7,840            -             -              -         8,000
Net loss for the year                      -           -             -            -             -        (69,885)      (69,885)
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, December 31, 2001       149,440,400     149,440       (73,465)           -             -        (69,885)        6,090
Capital stock issued pursuant
to a private placement
               - at $0.05            480,000         480        23,520            -             -              -        24,000
Net loss for the year                      -           -             -            -             -        (30,090)      (30,090)
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, December 31, 2002       149,920,400     149,920       (49,945)           -             -        (99,975)            -
Net income for the year                    -           -             -            -             -            108           108
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, December 31, 2003       149,920,400     149,920       (49,945)           -             -        (99,867)          108
Net loss for the year                      -           -             -                          -        (36,453)      (36,453)
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, December 31, 2004       149,920,400     149,920       (49,945)           -             -       (136,320)      (36,345)
Capital stock issued pursuant
to conversion of convertible
debentures     - at $0.05          1,145,424       1,146        56,125            -             -              -        57,271
Net loss for the year                      -           -             -            -             -        (34,650)      (34,650)
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, December 31, 2005       151,065,824     151,066         6,180            -             -       (170,970)      (13,724)
Capital stock retired to the
treasury                        (116,000,000)   (116,000)       87,000            -             -              -       (29,000)
Shares subscribed                          -           -             -      350,000             -              -       350,000
Subscription receivable                    -           -             -            -      (100,000)             -      (100,000)
Net loss for the period                    -           -             -            -             -        (23,502)      (23,502)
                                 ___________   __________    _________     ________    __________    ___________     _________

Balance, March 31, 2006           35,065,824   $  35,066     $  93,180     $350,000    $ (100,000)   $  (194,472)    $ 183,774
                                 ===========   =========     =========     ========    ==========    ===========     =========

*    The common stock issued has been retroactively restated to reflect a
     forward stock split of 1,500 new shares for one old share, effective on
     January 5, 2001, and a forward split of 4 new shares for one old share,
     effective February 20, 2006 (Note 3).

**   The par value of common stock has been retroactively restated to reflect a
     change from no par value to a par value of $0.001 per share.

</TABLE>


                                       8


<PAGE>


                               RADIAL ENERGY INC.
                       (formerly BV Pharmaceutical, Inc.)
                          (A Development Stage Company)
                    NOTES TO THE INTERIM FINANCIAL STATEMENTS
                             March 31, 2006 and 2005
                                   (Unaudited)
                             (Stated in US Dollars)


Note 1        INTERIM REPORTING

              The accompanying unaudited interim financial statements have been
              prepared by Radial Energy Inc. (the "Company") pursuant to the
              rules and regulations of the United States Securities and Exchange
              Commission. Certain information and disclosures normally included
              in annual financial statements prepared in accordance with
              accounting principles generally accepted in the United States of
              America have been condensed or omitted pursuant to such rules and
              regulations. In the opinion of management, all adjustments and
              disclosures necessary for a fair presentation of these financial
              statements have been included. Such adjustments consist of normal
              recurring adjustments. These interim financial statements should
              be read in conjunction with the audited financial statements of
              the Company for the fiscal year ended December 31, 2005.

              The results of operations for the three months ended March 31,
              2006 are not indicative of the results that may be expected for
              the full year.

Note 2        CONTINUANCE OF OPERATIONS

              These interim financial statements have been prepared in
              accordance with generally accepted accounting principles
              applicable to a going concern, which assumes that the Company will
              be able to meet its obligations and continue its operations for
              its next twelve months. Realization values may be substantially
              different from carrying values as shown and these financial
              statements do not give effect to adjustments that would be
              necessary to the carrying values and classification of assets and
              liabilities should the Company be unable to continue as a going
              concern. At March 31, 2006, the Company had not yet achieved
              profitable operations, has accumulated losses of $194,472 since
              its inception and expects to incur further losses in the
              development of its business, all of which casts substantial doubt
              about the Company's ability to continue as a going concern. The
              Company's ability to continue as a going concern is dependent upon
              its ability to generate future profitable operations and/or to
              obtain the necessary financing to meet its obligations and repay
              its liabilities arising from normal business operations when they
              come due. The Company intends to obtain additional financing by
              the sale of its common stock through a private placement commenced
              on February 21, 2006 (Note 3).

Note 3        CAPITAL STOCK

              Effective on January 5, 2001, the Company forward split its issued
              common stock on the basis of 1,500 new for one old.

              On May 25, 2004, the Company amended its authorized capital stock
              to 75,000,000 common shares with a par value of $0.001 per share.
              The number of authorized shares and the par value per share as
              referred to in these financial statements has been restated
              wherever applicable to give retroactive effect to this amendment.


                                       9


<PAGE>


              On February 10, 2006, the Company repurchased a total of
              29,000,000 pre-forward split (116,000,000 post-forward split)
              common shares at $0.001 per share from the previous President of
              the Company by the issuance of a promissory note for $29,000
              bearing interest at 8% per annum and due August 10, 2006. The
              Company repaid $20,000 of the promissory note on March 27, 2006,
              which was accepted as payment in full. Consequently the balance of
              the note and related interest was written off during the three
              months ended March 31, 2006.

              Effective on February 20, 2006, the Company forward split its
              issued common stock on the basis of four new for one old. The
              number of shares referred to in these financial statements has
              been restated wherever applicable to give retroactive effect on
              the forward stock splits. There was no effect on the Company's
              authorized share capital.

              The retroactive restatement of the issued common shares is
              required by the Securities and Exchange Commission's Staff
              Accounting Bulletin, Topic 4c. In actuality, the forward stock
              split, of four for one is effective after the Company's repurchase
              of 29,000,000 pre-forward split (116,000,000 post-forward split
              common shares). Consequently, the number of shares actually issued
              immediately prior to the split was 8,766,456 pre-forward split
              common shares (35,065,824 post-forward split common shares). The
              actual number of common shares, both pre-forward split and
              post-forward split, are less than the number of common shares
              authorized of 75,000,000.

              On February 10, 2006, the Company approved a private placement
              offering of up to 8,000,000 units at $0.25 per unit for maximum
              proceeds of $2,000,000. The minimum offering is $100,000. Each
              unit consists of one common share and one stock purchase warrant
              exercisable for two years into one common share at $0.30 per
              share. The private placement offering commenced on February 21,
              2006 and at March 31, 2006, the Company had received shares
              subscriptions for $350,000. Of the $350,000 shares subscriptions,
              cash consideration totalling $250,000 had been received at March
              31, 2006. Subsequent to March 31, 2006, the Company received
              additional share subscriptions for $1,000,000.

              On March 29, 2006, the officers of the Company approved a plan of
              merger between the Company and Radial Energy Inc. a wholly-owned
              inactive subsidiary of the Company incorporated in the State of
              Colorado on April 10, 2006 by the Company. Under the plan of
              merger, the shares of Radial Energy Inc. were cancelled and the
              shareholders of the Company received one share of the newly-merged
              company for every share of BV Pharmaceutical, Inc. held. The
              purpose of the merger was to facilitate a name change to Radial
              Energy Inc.

Note 4        RELATED PARTY TRANSACTION

              During the three months ended March 31, 2006, the Company incurred
              $9,000 (March 31, 2005: $Nil) in consulting fees charged by a
              former director of the Company.

Note 5        COMMITMENTS

              By an employment agreement dated March 10, 2006 with the President
              of the Company, and effective April 1, 2006, the Company will pay
              $180,000 per year plus annual bonuses as determined by the Board
              of Directors of the Company. In addition, the President will
              receive a $400 per month auto allowance, $800 per month insurance
              reimbursement and a minimum $1,000 per month for rental and
              administrative expenses to maintain an office. The Company may
              also issue stock options to the President as deemed appropriate by
              the Board of Directors. The term of the agreement is 3 years.


                                       10


<PAGE>


Note 6        SUBSEQUENT EVENTS - Note 3

              i)  By a letter of intent dated April 19, 2006, the Company agreed
                  to enter into a Joint Operating Agreement ("JOA") which was
                  formalized on May 11, 2006, with Peruvian and American
                  companies to acquire a 20% working interest and 18% revenue
                  interest in an oil project located in Peru by the funding the
                  acquisition of certain equipment to be used for drilling,
                  testing and evaluation of the first well on the property in
                  the amount of $1,650,000. Of the total, $900,000 is due upon
                  the signing of the JOA (paid subsequent to March 31, 2006) and
                  the remainder will be paid as costs are incurred on the well.

                  After the drilling of the first well is complete, the Company
                  will have the option whether to proceed with the project by
                  funding the drilling, testing and evaluation of another two
                  wells on the property for an additional $1,650,000.
                  Thereafter, the Company will have the option to pay for its
                  20% working interest share of the development and operation of
                  the project.

                  In the event the Company and the transacting parties decide
                  that the project is not feasible, the equipment acquired will
                  be sold and the Company will be entitled to 67% of the
                  proceeds.

                  The completion of a JOA is subject to certain due diligence
                  procedures to be carried out by the transacting parties.

              ii)By a business consulting agreement dated April 1, 2006, the
                  Company will pay $10,000 per month for investor relations
                  services for a term of two years.

Note 7        NON-CASH TRANSACTIONS

              Investing and financing activities that do not have a direct
              impact on current cash flows are excluded from the statements of
              cash flows. During the period ended March 31, 2006, the following
              transactions were excluded from the statement of cash flows:

              i)  the Company repurchased 116,000,000 common shares by the
                  issuance of a promissory note for $29,000.

              ii)the Company recorded shares subscription receivable of $100,000
                  pursuant to a share subscription agreement received.


ITEM  2      MANAGEMENT'S DISCUSSION OF OPERATIONS AND FINANCIAL CONDITION

DESCRIPTION OF BUSINESS

Radial Energy Inc. (formerly BV Pharmaceutical, Inc.) (the "Company")is a Nevada
corporation, which was originally formed on June 30, 2000 under the name of All
Printer Supplies.com. As All Printer Supplies.com, the company sought a
consulting opportunity for products and supplies to be offered on the internet,
but the economy at the time, due the demise of many "dot com" companies and
businesses, and the poor market conditions, was never able to launch its
business. On April 17, 2003, the Company changed its name to BV Pharmaceutical,
Inc. On March 29, 2006, the officers of the Company approved a plan of merger
between the Company and Radial Energy Inc., a wholly owned inactive subsidiary
of the Company incorporated by the Company in the State of Colorado on April 10,
2006, to facilitate the change of name to Radial Energy Inc. The Company was
issued 100 shares of the subsidiary for a consideration of $1.00. The 100 shares
were subsequently cancelled upon completion of the merger.


                                       11


<PAGE>


The Company's principal place of business is located at 1313 East Maple Street,
Bellingham, Washington, USA, 98225. The Company was organized to engage in any
lawful corporate business. The Company, has been in the developmental stage
since inception and has a very limited operating history and limited revenues.
The Company has a fully developed business plan, is operational and receiving
revenue. The company has $194,472 in losses to date.

The Company has had limited start-up operations and is considered a development
stage Company. The Company was originally capitalized at 100,000,000 shares of
Common Stock, with no par value. On May 25, 2004 the amended Articles of
Incorporation were filed with the state of Nevada to decrease the number of
authorized capital stock to 75,000,000 common shares with $0.001 par value. By
reducing the number of shares and establishing a par values for the shares, the
Company's annual filing fee with the Nevada Secretary of State was reduced. The
amendment was a cost-saving measure only. The only impact on the shareholders
was a reduction of the total authorized shares. While this reduced the shares
available for issuance, it also limited the possible dilution which could be
suffered by the shareholders. The Company believes the amendment had no material
impact on the Company, its operations, proposed operations or the rights of
shareholders.

ORGANIZATION

The Company was incorporated in the State of Nevada on June 30, 2000, for the
purpose of providing consulting services to businesses, and engaging in any
other lawful activity.

PRINCIPAL PRODUCTS AND SERVICES

The Company is currently building a new website at www.radialenergyinc.com to
reflect management's current strategic outlook and planned shift towards the
energy sector. The Company has abandoned its previous web-site of
www.yourcloneguard.com. The Company continues to provide information and
services in the areas of personal DNA collection, analysis, profiling, banking
and DNA profile database maintenance in addition to its seeking out interests in
the energy sector.

The Company currently offers two services. The first being an in home self test
DNA Profile Kit with banking (storage). The initial price for this service is
currently US$120. The second service, performed by a professional, allows for
the collection, analysis, profiling, banking, and DNA profile database
maintenance. This service will assist the client in establishing a chain of
custody. Through this service the Company will provide secure access to a
client's personal DNA profile, with documented chain of custody established,
should at some point in the future the need arise to provide evidence of prior
ownership. The initial price for this service is currently US $280.

IN HOME SELF TEST DNA PROFILE KIT AND BANKING.

The Kit will contain buccal sample swabs, sample collection technique indicator,
pre-paid return envelope, a collection seal, along with easy to follow step by
step directions to take a sample.

The sample process of collection is simple, fast, and non-intrusive. Collection
takes place by way of a home self-test kit, where a cotton swab (a buccal
swab)is gently wiped across the inside of the Client's cheek. The swab, which
contains your saliva and the DNA sample, is then labeled and mailed to the
Company for banking (storage). The test process and results would not be
considered suitable for use in a court of law. A certificate with the owner's
name, reference and identification number and other information will be mailed
back to the client.


                                       12


<PAGE>


The reasons for the use of the in home self test DNA Profile Kit and banking
service would include the following: 1) storage of a person's DNA; 2) peace of
mind; 3) permanent identifier of family member's DNA; 4) a tool for
identification of missing persons; 5) a genetic history of an elder family
member that may provide clues to inherited diseases; and 6) other genetic
issues.

CHAIN OF CUSTODY DNA PROFILING AND BANKING

Upon receipt of the client's registration for the service, the Company will set
up a DNA sample collection appointment at a hospital, laboratory or clinic near
the client. At the time of collection, the client will be required to provide
identification in the form of birth certificate, social security card or drivers
license. A DNA sample will be collected by way of a buccal cheek swab and the
client will be fingerprinted and photographed. The sample will be labeled,
securely stored and then sent to an independent third party testing facility
where it will be analyzed and a DNA profile will be determined, thereby
establishing the DNA pattern in a format recognized by the international
scientific and legal communities. We currently intend to use Orchid Helix's
testing facilities to perform these services. We have no agreement with Orchid
Helix. This collection and testing procedure establishes a date and time of
submission as evidence of prior ownership. The sample will be sealed and, along
with the results, will be stored for a period of 20 years. The results will be
cross checked with our database for fraud and duplicate submissions and then
added to our database. The Company will provide the client with a DNA Profile
Bank Certificate outlining the results of the client's personal, unique and
original DNA profile.

Results from home DNA tests are normally not guaranteed admissible in a court of
law due to the lack of the "chain of custody". The chain of custody refers to
the legal requirements necessary to establish and document the various persons
and methods used to handle and process the individual sample. A legally
admissible "chain of custody" for a sample requires the samples to be collected
in the presence of a third neutral party at a lab or hospital facility where all
parties are photographed to verify their identity.

The reasons for the use of the Chain Of Custody DNA Profiling and Banking
service would include the following; 1) Use as evidence of DNA theft or
misappropriation; 2) Proof of prior ownership; 3) Maternity or paternity cases;
or 4) Forensic cases.

We estimate the entire DNA Process for either of the services will take
approximately four to eight weeks from the time of DNA sample collection.

These services will be charged by debit or credit card or purchased by cashier's
check or money order.

DNA CLONING

We believe the cloning issue is confusing and fraught with ethical concerns. We
plan to provide information to help simplify the issue and provide more
expansive information to familiarize persons concerned about the cloning issue
and protecting their personal DNA against cloning. The process of DNA
collection, analysis and profiling can be an invasive, frightening and confusing
process for many. We believe we can familiarize the potential client with the
required steps and the need for the Company's DNA profile and banking service.

We believe it is extremely difficult to prevent a determined collector from
obtaining samples of DNA, since all complex living creatures constantly leave
traces of DNA throughout their environment in the form of hair, skin, saliva,
etc. However, we believe you can help deter persons who have illegally obtained
a sample of your DNA from trafficking in these samples, or in pursuing illegal
activities, such as cloning of the samples, by establishing your personal DNA
profile to show prior ownership.


                                       13


<PAGE>


DISTRIBUTION

We plan to deliver our services through licensing the service to third parties
on a geographic basis; that is, we will grant licenses to persons or business
entities to offer our services in certain, specific geographic areas, such as,
the Province of Alberta, Canada. We have not yet established any specific
geographic areas, and intend to do so only when we have a third party interested
in obtaining a license for a specific area. We do not currently have any
licenses or licensees, and have not been in contact with or negotiated with
anyone for any such license. We have not conducted any market testing to
determine the size of the market for our services.

On July 15, 2003, the Company entered into a license agreement with Mr. Matt
Sutton whereby we granted him a non-exclusive license to market services
relating to the collection of DNA samples and related data. The agreement is for
a term of one (1) year, commencing August 15, 2003, and the license fee due
under the agreement is US$2,000.00 per month. The agreement with Mr. Sutton has
terminated and will not be renewed. Mr. Sutton made no sales of the Company's
services. The license for Mr. Sutton was not renewed because he decided to
pursue other business interests. We do not believe this lack of renewal will
have any material impact on the Company. Since December 31, 2005, the Company
has received orders, sold and received full payment for Seventy-four(74)of its
In Home Self Test Kits. The most recent sale date for an In Home Self Test Kit
was March, 2006. During the period ending March 31, 2006, the Company received
payments of $8,500 for the sale in home test kits.

NEW PRODUCTS OR SERVICES

Other than the products and services described in this From 10-QSB, we currently
have no new products or services announced or planned to be announced to the
public.

COMPETITIVE BUSINESS CONDITIONS

We will face competition from all aspects of the emerging DNA-related business
and industry. We will compete with pharmaceutical and other science or
technology-related companies that have superior DNA-related experience and/or
services which they now, or may, in the future, offer to their potential or
existing customers. Many of these companies may in time offer free information
and DNA-related storage facilities to their customers. Many of these companies
have other sources of revenues and we rely only on the fees generated through
our proposed DNA information and database services. In addition, these companies
may have better marketing and distribution channels. There can be no assurance
that we will be able to compete effectively in this highly competitive industry,
which could have a material adverse impact upon market acceptance of our
proposed business.

Our main, existing and potential competitors for our proposed DNA testing,
profiling and banking business are any business in the pharmaceutical business
or distribution of pharmaceutical products business. Some of the primary DNA
service and information providers and competitors are: DNA Testing Centre, Inc.
- www.dnatestingcentre.com, GeneTree DNA Testing Center - www.genetree.com,
Metaphase Genetics - www.metaphasegenetics.com, and Genex Diagnostics SwabTest -
www.swabtest.com, and DNA Diagnostic Center - www.dnacenter.com.

OUR COMPETITIVE POSITION

We believe competition takes place on many levels, including pricing,
convenience in obtaining information, specialization, and breadth of services
offered. We intend to serve as a content aggregator for DNA-related information
and provide what we believe is an unbiased comprehensive information source, as
well as marketplace and facilitator for DNA-related information.


                                       14


<PAGE>


Our objective is to provide a service that helps the consumer cut through the
often perceived clutter, confusion and noise of the marketplace and help them
confidentially and quickly bring each person to a point where they can make an
informed decision if the services offered are appropriate for them.

By offering a specialized DNA storage and information service, we will be
targeting those consumers who are looking to establish their DNA profile and
banking of that profile. We believe that consumers will pay for a service that
is specialized, unbiased and comprehensive and one that helps them cut through
the perceived clutter, confusion and noise of the marketplace and help them
confidentially and quickly make an informed decision if the DNA testing and
profiling services offered are appropriate for them.

SOURCES AND AVAILABILITY OF RAW MATERIALS

As of the date of this quarterly report, we have established initial contact
with DNA sample kit suppliers and DNA testing facilities. We have not entered
into any arrangement or agreements to date.

CUSTOMER BASE

From December 31, 2005 to March 31, 2006, the Company has received orders,
amounting to $8,500 in sales revenue, for its In Home Self Test Kit. We have
received payment in full for the orders. We do not anticipate we will depend on
one or a few major customers. There can be no assurance that this assumption is
correct.

Our intended principal market of customers is expected to be the people who are
aware of the problem with identity theft, those with concerns about the health
and health risk factors of their relatives and unborn children and those wishing
to preserve their DNA profile in a data bank for future uses. We have not
performed any marketing studies to assess whether a potential market exists for
our proposed services, but we believe that there is such a market based on the
existence of other data banks and the number of articles about DNA storage and
identity theft management as seen in the media. We do not intend to perform any
marketing studies prior to beginning operations. Based on the costs of similar
services, we believe we can sustain a market for our services.

INTELLECTUAL PROPERTY

We do not have any trademarks, patents, licenses, royalty agreements, or other
proprietary interests.

GOVERNMENTAL REGULATION ISSUES

We are not now affected by direct government regulation. Based on our research,
we do not believe the products and services we intend to offer require approval
from the Food and Drug Administration.

ENVIRONMENTAL LAW COMPLIANCE

To the extent which environmental compliance may be necessary, we do not
anticipate any significant compliance expense.

EMPLOYEES

The Company does not have any employees.


                                       15


<PAGE>


REPORTS TO SECURITY HOLDERS

As of February 11, 2005, the Company became effective and is a reporting company
under the requirements of the Exchange Act and will file quarterly, annual and
other reports with the Securities and Exchange Commission. Our annual report
will contain the required audited financial statements. We are not required to
deliver an annual report to security holders and will not voluntarily deliver a
copy of the annual report to the security holders. The reports and other
information filed by us will be available for inspection and copying at the
public reference facilities of the Commission, 450 Fifth Street, N.W.,
Washington, D.C. 20549.

Copies of the material may be obtained by mail from the Public Reference Section
of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, at
prescribed rates. Information on the operation of the Public Reference Room may
be obtained by calling the SEC at 1-800-SEC-0330. In addition, the Commission
maintains a World Wide Website on the Internet at http://www.sec.gov that
contains reports, proxy and information statements and other information
regarding registrants that file electronically with the Commission.

PLAN OF OPERATIONS

The discussion contained in this quarterly report contains "FORWARD-LOOKING
STATEMENTS" that involve risk and uncertainties. These statements may be
identified by the use of terminology such as "BELIEVES," "EXPECTS," "MAY,"
"SHOULD" or "ANTICIPATES" or expressing this terminology negatively or similar
expressions or by discussions of strategy. The cautionary statements made in
this quarterly report are applicable to all related forward-looking statements
wherever they appear in this quarterly report. Our actual results could differ
materially from those discussed in this quarterly report.

We are a development stage company with limited operations or revenues. We are
unable to satisfy cash requirements without management's financial support or
other funding. Our management and certain investors have made $149,975 of
capital contributions to our business. The Company has raised the total of
$99,975 through Private Placements (see page 32 of the SB-2 filing "Recent Sales
of Unregistered Securities") and in January of 2004 the Company issued two
convertible debentures in the principal amount of $25,000 each, at an interest
rate of 10% per annum, for a total principal amount of $50,000 to two separate
unrelated non-US parties. Subsequent to June 30, 2005, these convertible
debentures have been converted to the number of shares stated in the financials.

At March 31, 2006, the Company had not yet achieved profitable operations, has
accumulated losses of $194,472 since its inception and expects to incur further
losses in the development of its business, all of which casts substantial doubt
about the Company's ability to continue as a going concern. The Company's
ability to continue as a going concern is dependent upon its ability to generate
future profitable operations and/or to obtain the necessary financing to meet
its obligations and repay its liabilities arising from normal business
operations when they come due.

The Company has cash on hand in the amount of $191,244, which it currently
intends to use in furtherance of its proposed entry into the oil and gas
business. The Company has not yet determined the amount of funds it may allocate
to its DNA test kit business.

The plan of the Company is to obtain additional financing by the sale of its
common stock through a private placement which commenced on February 21, 2006.
The Company approved a private placement offering of up to 8,000,000 units at
$0.25 per unit for proceeds of $2,000,000. The minimum offering is $100,000.
Each unit consists of one common share and one stock purchase warrant
exercisable for two years into one common share at $0.30 per share. In March
2006, the Company received share subscriptions for $350,000. Of the $350,000
share subscriptions, cash consideration totalling $250,000 was received during
March 2006. There is no assurance we will be able to raise additional funds or
that we will be able to raise sufficient capital to pursue proposed operations
in the oil and gas business.


                                       16


<PAGE>


In the event we need to raise additional funds, we have not yet determined how,
where or when we will obtain these funds. There is no assurance that we will be
able to obtain financing for our business development, if, as and when required,
or on terms favorable to the Company. If adequate funds are not available to us,
we believe that our business development could be adversely affected.

Our future capital requirements will also depend on one or more of the following
factors: - market acceptance of our services; - the extent and progress of our
research and development programs; - competing technological and market
developments; and - the costs of commercializing our services.

There can be no assurance that funding will be available on favorable terms to
permit successful commercialization of our DNA services or be successful in our
proposed business operations.

In addition, we have no further credit facility or other committed sources of
capital. We may be unable to establish credit arrangements on satisfactory
terms, if at all. If capital resources are insufficient to meet our future
capital requirements, we may have to raise additional funds to continue
development of our website. There can be no assurance that the funds will be
available on favorable terms, if at all.

To the extent that additional capital is raised through the sale of equity
and/or convertible debt securities, the issuance of the securities will likely
result in dilution to our shareholders.

There is no assurance that we will be successful in the marketing our DNA
profile services or licensing. We have no other proposed sources of revenue.
Therefore, if we are not successful in this regard, we will be unable to achieve
revenues under our current business plan.

We do not anticipate any significant research and development expenses over the
next twelve months. We do not expect to purchase or sell any plant and
significant equipment or make any significant changes in the number of employees
over the next twelve months.

SUBSEQUENT EVENTS

In May, 2006, the Company received share subscriptions for $1,000,000 for which
full cash consideration of $1,000,000 was received. The subscriptions are part
of the private placement which commenced on February 21, 2006. The Company
approved the private placement offering of up to 8,000,000 units at $0.25 per
unit for proceeds of $2,000,000. The minimum offering is $100,000. Each unit
consists of one common share and one stock purchase warrant exercisable for two
years into one common share at $0.30 per share.

On April 19, 2006, the Company entered into a Letter of Intent and thereafter on
May 11, 2006, into a Joint Operating Agreement (collectively the "Agreement")
with Zeigler-Peru, Inc. to form a joint venture for an oil drilling project in
Peru. Pursuant to the terms of the Agreement, the Company will obtain a 20%
working interest, and 18% revenue interest, in the Peruvian Huaya Anticline
Project, Block 100, oil prospect located near the analogous Maquia Field.

As consideration for this interest, which is only for one well, the Company will
pay US$1,650,000. On May 12, 2006, US$900,000 of the US$1,650,000 consideration
was paid.

Pursuant to the Agreement, upon completion and review of the drilling results of
the first well, the Company will have the option to participate in the drilling
of two additional wells. Should the Company opt to participate in the drilling
of the two additional wells, the Company will pay a further US$1,650,000.


                                       17


<PAGE>


Upon the completion of the drilling of well three, the Company will own a
pro-rata percentage of the drilling rig and related equipment. In the event the
joint venture is abandoned after drilling well three, the drilling rig and
related equipment will be sold for a reasonable amount and the Company will
receive 67% of the proceeds of sale.

After completion of the drilling and review of well three results, the Company
will have the option to participate in the drilling of additional wells, at a
cost of 20% of the development and operation costs of the new wells.

The Company will be a minority investor only in the project, and will not be the
operator.

Management believes the prospect is a low-risk opportunity to discover and
develop a field with production potential, but there can be no assurance the
prospect will achieve such potential.

It is anticipated that the first well will be drilled by the end of the 3rd
quarter of 2006, with production anticipated by year end.

The project encompasses a structural closure of 534 acres, with the potential
for 41 well locations. The Company believes there is currently an established
oil market offering international prices and an existing transportation network
with refineries nearby.

The Company contracted Gustavson and Associates of Boulder, Colorado, to perform
a reserve assessment which has reported favorable information.

There are no material relationships between the registrant or its affiliates and
any of the parties, other than in respect of the agreement.

The Company will seek to obtain the remaining funds necessary to perform under
the terms of the Agreement (US$1,650,000) through the private placement it
commenced on February 21, 2006.

DESCRIPTION OF PROPERTY

We do not own any real property at this time, and we conduct our business from
an office at the offices of our President, rent-free at this time.

The Company intends to lease space in the near future and will attempt to secure
space can on commercially reasonable terms and without undue operational
disruption.

PART II       OTHER INFORMATION

ITEM 6. - EXHIBITS AND REPORTS ON FORM 8-K

There was a report on Form 8-K filed on February 17, 2006. In a subsequent
material event, on April 21, 2006, the Company filed a report on Form 8-K.

The following exhibits are filed with this report:

      31.1 Certification of Chief Executive Officer pursuant to
           Section 302 of the Sarbanes-Oxley Act of 2002
      31.2 Certification of Chief Financial Officer pursuant to
           Section 302 of the Sarbanes-Oxley Act of 2002
      32.1 Certification of Chief Executive Officer pursuant to
           Section 906 of the Sarbanes-Oxley Act of 2002
      32.2 Certification of Chief Financial Officer pursuant to
           Section 302 of the Sarbanes-Oxley Act of 2002


                                       18


<PAGE>


ITEM 7. SIGNATURES


                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                   RADIAL ENERGY INC.
                                   (formerly BV Pharmaceutical, Inc.)



DATE: May 18, 2006                 /s/ G. LEIGH LYONS
                                   __________________________
                                       G. Leigh Lyons
                                       President and Director












                                       19